346例脑梗死患者静脉用药的相关因素分析

发布时间：2019-05-22 01:37

【摘要】：目的:分析346例脑梗死患者静脉用药情况,为脑梗死患者合理选用静脉用药物提供参考。方法:选取2012年1月—2013年2月间医院脑病科收治的脑梗死患者346例病历资料,统计患者的基本信息和静脉用药情况,以限定日剂量(DDD)计算用药频度(DDDs)和日均费用(DDDc)。结果:346例脑梗死患者静脉用药金额排序前3位的药物类型为中枢神经系统药物、中成药和抗感染药物,其中奥扎格雷钠在脑梗死患者静脉用药金额排序中居第3位,其DDDs排序靠前,具有疗效好、用药金额在患者可接受范围内和经济学属性佳的特点;乙酰谷酰胺的DDDs值为最大,DDDc值为最小,该药的经济学和药物治疗学属性均较为理想,为医院最常用的脑梗死患者辅助治疗药物;依达拉奉的用药金额、DDDc排序均居第1位,其用于治疗脑梗死的疗效较为显著,但经济学属性欠佳;单唾液酸四己糖神经节苷脂的用药金额、DDDs排序均居第2位,其DDDc值较大,价格较高,药物经济学属性不佳。结论:346例脑梗死患者的总有效率为97.11%,提示治疗用药和病情基本匹配,但由于脑梗死患者病情的复杂性,需多种药物联用治疗,因此临床应根据患者的疾病特点,合理选用静脉用药物。
[Abstract]:Objective: to analyze the intravenous drug use in 346 patients with cerebral infarction, and to provide reference for rational selection of intravenous drugs in patients with cerebral infarction. Methods: the medical records of 346 patients with cerebral infarction admitted to the Department of Encephalology from January 2012 to February 2013 were selected, and the basic information of the patients and the situation of intravenous drug use were counted. Calculation of drug frequency (DDDs) and daily average cost (DDDc). With limited daily dose (DDD) Results: the first three drug types in 346 patients with cerebral infarction were central nervous system drugs, proprietary Chinese drugs and anti-infective drugs, among which ozagrel sodium ranked third in the order of intravenous drug amount in patients with cerebral infarction. Its DDDs ranking is high, which has the characteristics of good curative effect, the amount of money used is within the acceptable range of patients and the economic attribute is good. The DDDs value of acetylglutamine is the largest and the DDDc value is the smallest. The economic and pharmaceutical therapeutic properties of acetylglutamine are ideal, and it is the most commonly used auxiliary treatment drug for patients with cerebral infarction in hospital. The amount of money used in Edaravone ranked first in the order of DDDc. The curative effect of Edaravone in the treatment of cerebral infarction was more significant, but the economic attribute was not good. The amount of monosialic acid tetrahexose gangliosides ranked second in the order of DDDs, the DDDc value was large, the price was higher, and the pharmacoeconomic properties of monosialic acid tetrahexose gangliosides were not good. Conclusion: the total effective rate of 346 patients with cerebral infarction is 97. 11%, suggesting that the treatment of cerebral infarction is basically matched with the condition of the disease. However, due to the complexity of the condition of patients with cerebral infarction, a variety of drugs are needed to treat the patients, so the clinic should be based on the characteristics of the patients. Reasonable selection of intravenous drugs.
【作者单位】：苏州市中医医院药学部;
【分类号】：R743.33

【相似文献】